Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Dooijewaard

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Thrombosis and Haemostasis|January 23, 1991
Physical exercise induces enhancement of urokinase-type plasminogen activator (u-PA) levels in plasmaG Dooijewaard, A de Boer, P N Turion, et al.
Thrombosis and Haemostasis|October 1, 1991
Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator releaseM Levi, A W Lensing, H R Büller, et al.
Thrombosis and Haemostasis|February 1, 1994
Differences in u-PA and t-PA increase during acute exercise: relation with exercise parametersP J van den Burg, G Dooijewaard, M van Vliet, et al.
Blood|December 1, 1990
Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation productsV W van Hinsbergh, K A Bauer, T Kooistra, et al.
Thrombosis and Haemostasis|December 1, 1995
An amino acid polymorphism in histidine-rich glycoprotein (HRG) explains 59% of the variance in plasma HRG levelsB C Hennis, D I Boomsma, P A van Boheemen, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|September 14, 2001
Urokinase-type plasminogen activator system predicts risk of cardiovascular events in patients with angina pectoris: results of the ECAPTURE study. European Concerted Action on Prevention from Thrombosis by URokinase EnhancementM P de Maat, G Dooijewaard, P Meijer, et al.
Thrombosis and Haemostasis|April 30, 1984
Stanozolol-induced changes in fibrinolysis and coagulation in healthy adultsC Kluft, F E Preston, R G Malia, et al.
The Journal of Clinical Investigation|November 1, 1987
alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorderC Kluft, H K Nieuwenhuis, D C Rijken, et al.
Thrombosis and Haemostasis|August 2, 1993
Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjectsA de Boer, C Kluft, J Gerloff, et al.
Thrombosis and Haemostasis|January 1, 1994
Blood fibrinolysis and the response to desmopressin in glomerulonephritisE J Brommer, A W Van den Wall Bake, G Dooijewaard, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Thrombosis and Haemostasis|January 23, 1991
Physical exercise induces enhancement of urokinase-type plasminogen activator (u-PA) levels in plasmaG Dooijewaard, A de Boer, P N Turion, et al.
Thrombosis and Haemostasis|October 1, 1991
Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator releaseM Levi, A W Lensing, H R Büller, et al.
Thrombosis and Haemostasis|February 1, 1994
Differences in u-PA and t-PA increase during acute exercise: relation with exercise parametersP J van den Burg, G Dooijewaard, M van Vliet, et al.
Blood|December 1, 1990
Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation productsV W van Hinsbergh, K A Bauer, T Kooistra, et al.
Thrombosis and Haemostasis|December 1, 1995
An amino acid polymorphism in histidine-rich glycoprotein (HRG) explains 59% of the variance in plasma HRG levelsB C Hennis, D I Boomsma, P A van Boheemen, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|September 14, 2001
Urokinase-type plasminogen activator system predicts risk of cardiovascular events in patients with angina pectoris: results of the ECAPTURE study. European Concerted Action on Prevention from Thrombosis by URokinase EnhancementM P de Maat, G Dooijewaard, P Meijer, et al.
Thrombosis and Haemostasis|April 30, 1984
Stanozolol-induced changes in fibrinolysis and coagulation in healthy adultsC Kluft, F E Preston, R G Malia, et al.
The Journal of Clinical Investigation|November 1, 1987
alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorderC Kluft, H K Nieuwenhuis, D C Rijken, et al.
Thrombosis and Haemostasis|August 2, 1993
Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjectsA de Boer, C Kluft, J Gerloff, et al.
Thrombosis and Haemostasis|January 1, 1994
Blood fibrinolysis and the response to desmopressin in glomerulonephritisE J Brommer, A W Van den Wall Bake, G Dooijewaard, et al.
Pageof 5